Navigation Links
Chemo plus radiation before surgery increases tumor response for rectal cancer
Date:9/26/2011

e, compared to the Cap45 treatment. Oxaliplatin, given as part of the Capox50 treatment, was shown to immediately increase side effects, with some cases of severe diarrhea, and was not effective in increasing the chance of local tumor sterilization.

However, the increase of radiation dose from 45 to 50 Gy in five weeks was effective, well tolerated and did not extend the duration of treatment.

"The results of this trial, when analyzed together with the Italian STAR01 and the American NSABP R04 randomized trials, bring solid scientific evidence that a 'CAP50 regimen' should be the standard treatment for locally advanced rectal cancer. Using Capecitabine avoids the intravenous injection of fluorouracil, while a radiation dose of 50 Gy in 25 fractions over five weeks increases the chance of tumor sterilization and limits the risk of local recurrence to 5 percent or less," Dr. Gerard said.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence
2. Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients
3. CWRU research examines over-the-counter drugs effect on chemos side effects
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Fish oil reduces effectiveness of chemotherapy
6. Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer
7. Chemotherapy is as effective before breast cancer surgery as after
8. Chemotherapy can impair speech
9. Going Straight to Chemo May Be Better for Certain Breast Cancers
10. UCSF study shows greater impact of chemotherapy on fertility
11. Nurses at Risk for Accidental Exposure to Chemo Drugs: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... The Maricopa ... aging out of the foster care system to get into and complete college. ... was introduced at an event today with partners from across the valley. , ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... professional and in-depth research report. The report provides basic information such as ... etc. This report covers the global (US, Europe, Japan etc) industry analysis ...
(Date:7/27/2015)... ... 27, 2015 , ... Throughout its 20 year history, Doctors on Liens ... on a lien basis. As the personal injury and medical industries have changed, ... to orthopedists, to pain management physicians, to psychologists and more. And while many ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Recently, 10 ... Nine other respected water brands also made the organization’s list. As its name clearly ... label options available. Here is a description of the top three brands, along with ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... medical and diagnostics applications is rapidly increasing and is driven by focused research ... they are increasingly being evaluated for use in bio implants. MWCNTs are used ...
Breaking Medicine News(10 mins):Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3
... and Welfare (AIHW) it is found that Obstetrics department generates ... new report shows that one in five cases of negligence ... medical field was going through a period of crisis. In ... of doctors' negligence insurance for which the doctors were threatening ...
... to clinical trials, Union Minister for Health and Family Welfare ... as a guinea pig'//. ,'If you do clinical trials ... very guarded. We will not allow our population to suffer,' ... have laws and we are going to strengthen them,' the ...
... a new test to identify patients who develop bowel cancer ... fault is unveiled ,today//. ,An Edinburgh University team ... the New England Journal of Medicine. They explained that the ... then get the best treatment and will help identify relatives ...
... has said that the insurance industry is unfair in dealing ... insurance or are being asked to pay higher premiums even ... ,A survey conducted by the charity found that 90 percent ... say that it is not only cancer patients, but anyone ...
... consumption without a break is threatening to compete with ... manufactured by Wyeth Pharmaceuticals, is awaiting approval by health ... slip to the monthly period! Currently unavailable in neither ... period marked by extensive clinical trials. , ,This ...
... details about running a joint campaign fronted by the ... of family meals as a method of improving the ... departure for government public health campaigns in its tie-up ... report, which stated that such partnerships should be encouraged ...
Cached Medicine News:Health News:A New Test Developed to Identify Suspected Bowel Cancer Patients 2
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... Oct. 13, 2011 K-V Pharmaceutical Company (the ... of Obstetricians and Gynecologists (ACOG) and Society for ... that ensures healthcare providers, patients, and the payer ... information update emphasizes that previous ACOG and SMFM ...
... 13, 2011 IVD Technology , ... diagnostics technologies including research, development, and manufacturing, today announced ... emerging trend in the industry – ... (CONTACT:   http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ) The featured speaker ...
Cached Medicine Technology:K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8Distinguished Speaker Dr. Elizabeth Mansfield Joins IVD Technology for Upcoming Webcast: The Regulation of Companion Diagnostics: Current Status and Updates 2Distinguished Speaker Dr. Elizabeth Mansfield Joins IVD Technology for Upcoming Webcast: The Regulation of Companion Diagnostics: Current Status and Updates 3